Agritek Holdings, Inc. (AGTK) www.AgritekHoldings.com, a fully integrated, active real estate investor and white label provide for popular hemp brands, today announced that the Company has completed the acquisition and definitive agreement to acquire all of the issued and outstanding shares of Full Spectrum Biosciences Inc., a Colorado based company focused on blockchain, genetic mapping of cannabis strains and IP formulation of premium brands.
The closing of the acquisition and definitive agreement between Agritek Holdings and Full Spectrum Biosciences included an all-equity transaction of 10M shares of Agritek Holdings for acquiring 100% of the issued and outstanding shares of Full Spectrum Biosciences Inc. including Intellectual property assets, Colorado hemp license renewal, proprietary formulations, and brands. Full Spectrum Biosciences will become a wholly owned subsidiary of Agritek Holdings, Inc. for consolidation of revenue. Shareholders of both companies will benefit from the combined companies’ expanded product offerings, infrastructure, revenue streams, and consumer reach. Through the acquisition, Agritek Holdings will now own the exclusive portfolio of premium brand formulations with Full Spectrum Biosciences operating as Agritek’s health and wellness business.
“Full Spectrum Bioscience’s established premium wellness brands and formulations will now provide Agritek Holdings with an additional revenue platform from which the combined company will launch new hemp based nutraceutical products for growing consumer segment,” stated CEO, B. Michael Friedman.
“With COVID-19 officially declared a pandemic by the World Health Organization, Full Spectrum Biosciences will soon be releasing a proprietary cannabinoid-infused, aloe based hand sanitizer product containing cannabigerol, or CBG. The hand sanitizer will be released under the Company’s Rehab Rx brand with the first purchase orders already in place for delivery this month,” added Friedman.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Cannabinoids have potent antibacterial properties and studies have shown that cannabidiol (CBD) and cannabigerol (CBG) have potent effects against antibiotic resistant bacteria which makes it an ideal ingredient to add in the fight against bacterial infections. Recently, McMaster University researchers have identified an antibacterial compound made by cannabis plants that may serve as a lead for new drug development. An interdisciplinary team of McMaster researchers found that the chemical compound, or cannabinoid, called cannabigerol (CBG) is not only antibacterial but also effective in mice against a resilient family of bacteria known as methicillin-resistant Staphylococcus aureus (MRSA). CBG achieved this by targeting the cell membrane of the bacteria. These findings in the laboratory were supported when mice with an MRSA infection were given CBG. The findings were published in the journal American Chemical Society Infectious Diseases.
Further, a Journal of Natural Products research article, published in 2008 by the American Chemical Society, reported that cannabidiol (CBD) and cannabigerol (CBG), two of the most abundant cannabinoids found in hemp, “showed potent activity against a variety of MRSA strains.” Cannabinoids have been proven to have potent antibacterial properties, but this study shows that cannabinoids can be an effective ingredient to fight antibiotic resistant bacteria which is the leading cause of death in hospitals.
The journal went on to conclude that “Given the availability of Cannabis sativa strains producing high concentrations of nonpsychotropic cannabinoids, this plant represents an interesting source of antibacterial agents to address the problem of multidrug resistance in MRSA and other pathogenic bacteria. This issue has enormous clinical implications, since MRSA is spreading throughout the world and, in the United States, currently accounts for more deaths each year than AIDS. Although the use of cannabinoids as systemic antibacterial agents awaits rigorous clinical trials … their topical application to reduce skin colonization by MRSA seems promising.”
Source: Biospace
